Compare Automatic Data Processing Inc (ADP) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Eli Lilly And Co — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $107.69B), while Eli Lilly And Co trades at $1,221.25 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 10× Automatic Data Processing Inc's market cap, and Automatic Data Processing Inc pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| ADP | LLY | |
|---|---|---|
Market Cap | $107.69B | $1.08T |
Sector | Industrials | Health |
52-Week High | $309.03 | $1.24K |
52-Week Low | $188.79 | $639.43 |
Enterprise Value | $108.73B | $1.13T |
Dividend Yield | 2.51% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $269.14, down 1.66% on the day, with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings, beating estimates with EPS of $2.62 versus $2.57 expected, and revenue growth continues steadily. Analyst consensus is a $280.50 price target, though the majority rating is Hold. Recent news highlights dividend declarations and employment data reports.
Outlook remains positive due to consistent earnings beats and margin expansion, but high valuation multiples like a P/E of 24.78 pose a risk if growth slows. Key risks include economic sensitivity affecting payroll services demand and competitive pressures in HR solutions.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
